IP Library Granted Patent US 11,530,191
Granted Patent B2
US 11,530,191 · App. 17/026,690 · Granted Dec 20, 2022

Compounds and uses thereof for the modulation of hemoglobin

Inventors: Brian W. Metcalf (South San Francisco, CA); Zhe Li (San Diego, CA); Qing Xu (South San Francisco, CA); Stephen L. Gwaltney, II (South San Francisco, CA); Jason R. Harris (South San Francisco, CA); Calvin W. Yee (South San Francisco, CA)
Assignee: Global Blood Therapeutics, Inc.
C07D401/04A61K8/4913A61K31/445A61K31/5375C07C65/30C07D211/62C07D211/70C07D213/30C07D213/64C07D213/69C07D227/08C07D231/56C07D257/04C07D401/12C07D401/14C07D405/04C07D405/14C07D471/04C07D487/04C07F7/0812
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,530,191
App. No.
17/026,690
Granted
Dec 20, 2022
Kind
B2
Abstract

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Claims (5)

1. A compound selected from the group consisting of:

or an N oxide thereof, or a pharmaceutically acceptable salt of each thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or an N oxide thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.

3. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a compound of claim 1 , or an N oxide thereof, or a pharmaceutically acceptable salt of each thereof.

4. A method for treating sickle cell disease, the method comprising administering to a subject in need thereof a compound of claim 1 , or an N oxide thereof, or a pharmaceutically acceptable salt of each thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2022
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 061620/0186 →
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 22, 2021
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058575/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2021
From: METCALF, BRIAN W; LI, ZHE; XU, QING; GWALTNEY II, STEPHEN L.; HARRIS, JASON R.; YEE, CALVIN W.
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 058266/0396 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 9, 2020
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054664/0871 →
Continuity (6)
Continuation 15941433 · Mar 30, 2018
Continuation 14776603
Continuation In Part 13815770 · Mar 15, 2013
Provisional Application 61905802 · Nov 18, 2013
Provisional Application 61905803 · Nov 18, 2013
Related Publication 20210261520A1 · Aug 26, 2021